Research Solutions, Inc · NASDAQ:RSSS
Research Solutions — Derycz Scientific — Investor Presentation (June 2008)
20 slides from Research Solutions's investor presentation, Jun 18, 2008
Slide 1: Investor Presentation May 2008
INVESTOR PRESENTATION eS MAY 2008
Slide 2: Forward-looking statements safe harbor
In conjunction with the provisions of the safe harbor section of the private “securities litigation reform act of 1995, this document contains certain forwat looking statements pertaining to future anticipated projected plans, performance and developments, as well as other statements relating to fut
Slide 3: Derycz Scientific Mission
DERYCZ SCIENTIFIC MISSION 0) We are a content re-purposing company. Our mission is to develop the products, services and systems that facilitate the re-use of published content in a manner that helps organizations achieve their marketing, communication and research goals effectively and in complianc
Slide 4: Content Re-purposing
CONTENT RE-PURPOSIN | ©) Finding new uses » CONTENT RE-PURPOSING = Finding new uses for mankind’s published knowledge DERYCZ SCIENTIFIC SS
Slide 5: Market Position
MARKET POSITION | 0) CUSTOMERS DERYCZ SCIENTIFIC —
Slide 6: ABC Pharmaceuticals prescription drug example
ABC Pharmaceuticals has just released a prescription drug they believe is superior to that of an established competitor. a There are a few seminal scientific articles that prove this and ABC would like to distribute 100,000 print and electronic copies of these articles to physicians. HOW CAN THIS BE
Slide 7: Logistics Issues
LOGISTICS ISSUES: How does ABC pharma manage physicial distribution storage and logistics? DERYCZ SCIENTIFIC —
Slide 8: Acquisition discussions with European company
Derycz is currently in acquisition discussions with the owners of a profitable company in Europe to serve as a strategic partner in our launch into the European market. DERYCZ SCIENTIFIC ee )
Slide 9: Management team
» PETER DERYCZ - CHAIRMAN AND CEO 2 - ‘Twenty years of industry experience. Grew Infotrieve (a purveyor of scientific articles) to $32 million in ~ sales before selling to a group of Private Equity investors in 2003. » JAN PETERSON — DIRECTOR AND HEAD OF PUBLISHER RELATIONS Jan is an industry vetera
Slide 10: Milestones: Pools Press acquisition and revenues
» FEBRUARY 2007 Derycz Scientific acquires Pools Press, a commercial article printer » MARCH 2008 Derycz reports $8M in revenues for last nine months. Successfully files Registration Statement with SEC DERYCZ SCIENTIFIC SS
Slide 11: Progress on achieving original goals
HAS BEEN MADE ON ACHIEVING OUR ORIGINAL GOALS: [ ©) additional up-selling of related products and gross margins » Develop products and services with customer involvement » Become a publicly traded company DERYCZ SCIENTIFIC —_—_—__—
Slide 12: Goal: 100% penetration of top pharma and biotech
» Goal: 100% Penetration into all of the Top 50 Pharma and Top 100 Biotech companies by 2010. “As iste in Top 100 biotechnology companies and Top 50 Pharmaceutical Companies Charts & List, Med Ad News, Sep. 2007 DERYCZ SCIENTIFIC EE
Slide 13: Services: reprints, content distribution logistics, copyright, toolbox
REPRINTS | Continues to grow its customer and revenue bases. New services are being NINSi_ | launched quarterly as well as the announcement of a series of strategically important publisher relationships. Recently ranked #1 in Outsell study. Print-on-Demand Services for Copyright and Regulatory sensi
Slide 14: Quarterly revenue chart
222008 S208 04-2008 QH-ZNUT 022007 O3L007- aHLADOT 1-208 DERYCZ SCIENTIFIC —————
Slide 15: Established vendor and profitability outlook
+ Established vendor on purchasing systems of dozens of large healthcare companies + Acquisitions under discussion that are accretive to revenues and profits + Anticipate achievement of net quarterly profitability in Q3 or Q4 2008 DERYCZ SCIENTIFIC RS
Slide 16: Statement of operations
Loss from operations (103,484) (202,868) (602,617 Total other income (expenses) (34,343) 49,962 87,126 Net loss s (137,721) $ (152,902) $ (415,491) Basic and diluted net loss per $ (0.01) $ (0.01) $ (0.04) share Basic and diluted shares 12,561,813 12,510,305 10,625,003 outstanding DERYCZ SCIENTIFIC
Slide 17: Balance sheet
| ©) Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable s 1,678,861 ‘Outstanding on credit line 1,279,450 Total current liabilities 3,051,874 Total stockholders’ equity 3,828,105 Total liabilities and stockholders’ equity s 7,002,885 DERYCZ SCIENTIFIC s
Slide 18: Acquisition opportunities
WE ARE LOOKING AT SOME VERY INTERESTING ACQUISITION OPPORTUNITIES » TARGET 1 - EUROPE = Acquisition of a profitable Print on Demand and Logistics Company. Will give the company a springboard from which to grow into Europe and $18M in new revenues annually » TARGET 2-US Acquisition of a profitable Ou
Slide 19: Plan to increase revenues with core customers
Our plan is to increase revenues with our core customers. As our value-add increases, we expect our gross margins to increase as well. DERYCZ SCIENTIFIC )
Slide 20: Derycz Scientific
www.deryezscientific.com DERYCZ SCIENTIFIC SS
Derycz Scientific — Investor Presentation (June 2008) on 6ix